Published in Blood on June 08, 2006
Mouse models of human AML accurately predict chemotherapy response. Genes Dev (2009) 2.75
Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia. Proc Natl Acad Sci U S A (2008) 2.10
Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia. Blood (2010) 1.86
Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner. Blood (2011) 1.70
Targeting oncogenic Ras signaling in hematologic malignancies. Blood (2012) 1.67
Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood (2010) 1.60
Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion. Mol Cell Biol (2008) 1.53
C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci U S A (2011) 1.36
Functional specificity of ras isoforms: so similar but so different. Genes Cancer (2011) 1.30
Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice. Cancer Res (2007) 1.26
Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica (2010) 1.19
Modelling oncogenic Ras/Raf signalling in the mouse. Curr Opin Genet Dev (2009) 1.02
Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy. PLoS One (2009) 1.01
Palmitoylation of oncogenic NRAS is essential for leukemogenesis. Blood (2010) 0.95
Lyn- and PLC-beta3-dependent regulation of SHP-1 phosphorylation controls Stat5 activity and myelomonocytic leukemia-like disease. Blood (2010) 0.93
RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia. Blood (2008) 0.92
Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis. Leukemia (2015) 0.91
Relevant mouse model for human monocytic leukemia through Cre/lox-controlled myeloid-specific deletion of PTEN. Leukemia (2010) 0.90
Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol (2013) 0.85
The differential palmitoylation states of N-Ras and H-Ras determine their distinct Golgi subcompartment localizations. J Cell Physiol (2015) 0.82
ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia. Blood (2014) 0.81
Differential in vivo tumorigenicity of diverse KRAS mutations in vertebrate pancreas: A comprehensive survey. Oncogene (2014) 0.80
Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they? Haematologica (2012) 0.80
BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS. Am J Hematol (2014) 0.79
Oncogenic NRAS hyper-activates multiple pathways in human cord blood stem/progenitor cells and promotes myelomonocytic proliferation in vivo. Am J Transl Res (2015) 0.79
Nras overexpression results in granulocytosis, T-cell expansion and early lethality in mice. PLoS One (2012) 0.79
Activated N-Ras signaling regulates arterial-venous specification in zebrafish. J Hematol Oncol (2013) 0.78
Roles of palmitoylation and the KIKK membrane-targeting motif in leukemogenesis by oncogenic KRAS4A. J Hematol Oncol (2015) 0.78
Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R. Clin Cancer Res (2014) 0.77
What's different about atypical CML and chronic neutrophilic leukemia? Hematology Am Soc Hematol Educ Program (2015) 0.76
Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia. Oncotarget (2016) 0.76
BCR/ABL can promote CD19(+) cell growth but not render them long-term stemness. Stem Cell Investig (2016) 0.75
Natural history of chronic myelomonocytic leukemia: gene sequencing identifies multiple clonal molecular abnormalities associated with rapid progression to acute myeloid leukemia. Clin Case Rep (2014) 0.75
MEK1 is required for the development of NRAS-driven leukemia. Oncotarget (2016) 0.75
Translational hematology. Wien Med Wochenschr (2014) 0.75
ras genes. Annu Rev Biochem (1987) 22.59
ras oncogenes in human cancer: a review. Cancer Res (1989) 22.03
The World Health Organization (WHO) classification of the myeloid neoplasms. Blood (2002) 10.87
Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood (1998) 6.81
Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell (1987) 5.57
Ras proteins: different signals from different locations. Nat Rev Mol Cell Biol (2003) 5.55
Versatile retroviral vectors for potential use in gene therapy. Gene Ther (1994) 5.33
Species- and cell type-specific requirements for cellular transformation. Cancer Cell (2004) 4.25
K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev (1997) 4.24
Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest (2004) 3.47
Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A (2003) 3.46
Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. Mol Cell Biol (2001) 2.60
K-ras is essential for the development of the mouse embryo. Oncogene (1997) 2.57
Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? Trends Cell Biol (2004) 2.32
The murine N-ras gene is not essential for growth and development. Proc Natl Acad Sci U S A (1995) 2.18
RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood (2005) 1.85
Interactions between a nuclear transporter and a subset of nuclear pore complex proteins depend on Ran GTPase. Mol Cell Biol (1999) 1.83
The S6 kinase signaling pathway in the control of development and growth. Biol Res (2002) 1.83
Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines. J Exp Med (1998) 1.82
Generation of mammalian cells stably expressing multiple genes at predetermined levels. Anal Biochem (2000) 1.79
Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood (2000) 1.65
Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice. Blood (1999) 1.38
Improved expression in hematopoietic and lymphoid cells in mice after transplantation of bone marrow transduced with a modified retroviral vector. Blood (1999) 1.22
Hematopoietic transforming potential of activated ras in chimeric mice. Oncogene (1995) 1.18
Bcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy. Mol Cell Biol (1999) 1.17
Retroviral infection accelerates T lymphomagenesis in E mu-N-ras transgenic mice by activating c-myc or N-myc. Oncogene (1992) 1.10
The PEBP2betaMYH11 fusion created by Inv(16)(p13;q22) in myeloid leukemia impairs neutrophil maturation and contributes to granulocytic dysplasia. Proc Natl Acad Sci U S A (1998) 1.07
Modeling the dosage effect of oncogenes in leukemogenesis. Curr Opin Hematol (2004) 1.07
The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model. Oncogene (2002) 1.05
Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression. Leuk Res (2003) 1.05
Activated N-ras oncogene and N-ras proto-oncogene act through the same pathway for in vivo tumorigenesis. Oncogene (1996) 1.05
Repressible transgenic model of NRAS oncogene-driven mast cell disease in the mouse. Blood (2005) 1.02
Ras signaling, deregulation of gene expression and oncogenesis. Cancer Treat Res (2003) 0.96
Mutations and expression of the ras family genes in leukemias. Stem Cells (1996) 0.93
Dissecting the molecular mechanism of chronic myelogenous leukemia using murine models. Leuk Lymphoma (2002) 0.81
Ras as a target in cancer therapy. Crit Rev Oncol Hematol (2002) 0.80
A plant homeodomain in RAG-2 that binds Hypermethylated lysine 4 of histone H3 is necessary for efficient antigen-receptor-gene rearrangement. Immunity (2007) 3.54
p16(INK4a) translation suppressed by miR-24. PLoS One (2008) 3.08
Repeat organization and epigenetic regulation of the DH-Cmu domain of the immunoglobulin heavy-chain gene locus. Mol Cell (2007) 1.75
C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci U S A (2011) 1.36
Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice. Cancer Res (2007) 1.26
Beta-catenin expression results in p53-independent DNA damage and oncogene-induced senescence in prelymphomagenic thymocytes in vivo. Mol Cell Biol (2007) 1.21
Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors. Cancer Res (2009) 1.14
The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl. Blood (2002) 1.10
Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide. Cancer Res (2006) 1.10
A 220-nucleotide deletion of the intronic enhancer reveals an epigenetic hierarchy in immunoglobulin heavy chain locus activation. J Exp Med (2009) 1.03
Ubp43 regulates BCR-ABL leukemogenesis via the type 1 interferon receptor signaling. Blood (2007) 1.02
IRF-4 functions as a tumor suppressor in early B-cell development. Blood (2008) 1.01
Palmitoylation of oncogenic NRAS is essential for leukemogenesis. Blood (2010) 0.95
IRF-4 suppresses BCR/ABL transformation of myeloid cells in a DNA binding-independent manner. J Biol Chem (2011) 0.92
Cooperation between deficiencies of IRF-4 and IRF-8 promotes both myeloid and lymphoid tumorigenesis. Blood (2010) 0.91
Cannabinoid receptor 2 suppresses leukocyte inflammatory migration by modulating the JNK/c-Jun/Alox5 pathway. J Biol Chem (2013) 0.89
Effect of Ras inhibition in hematopoiesis and BCR/ABL leukemogenesis. J Hematol Oncol (2008) 0.87
Localization of BCR-ABL to F-actin regulates cell adhesion but does not attenuate CML development. Blood (2003) 0.85
Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice. Oncogene (2004) 0.85
Cutting edge: SWI/SNF mediates antisense Igh transcription and locus-wide accessibility in B cell precursors. J Immunol (2009) 0.83
c-CBL is not required for leukemia induction by Bcr-Abl in mice. Oncogene (2003) 0.82
Mouse model for NRAS-induced leukemogenesis. Methods Enzymol (2008) 0.82
Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia. J Clin Invest (2016) 0.81
Localized DNA demethylation at recombination intermediates during immunoglobulin heavy chain gene assembly. PLoS Biol (2013) 0.80
The role of RAS effectors in BCR/ABL induced chronic myelogenous leukemia. Front Med (2013) 0.78